The standard curative treatment strategy for selected patients with locally advanced non–small-cell lung cancer (NSCLC) is platinum-based chemotherapy with concurrent thoracic radiotherapy (TRT).
1,2 The initial report of the West Japan Thoracic Oncology Group (WJTOG) 0105
3 trial establishes weekly carboplatin plus paclitaxel combined with TRT as the standard regimen among the 3 regimens because of its favorable toxic effect profile. Other studies found that concurrent chemoradiotherapy (CRT) with former-generation chemotherapy regimens achieved median survival of 16.1 to 30.0 months and 7-year overall survival (OS) rates ranging from 12.0% to 23.1%.
4-6 However, limited data are available for patients who underwent concurrent CRT with third-generation chemotherapy who were followed up for more than 10 years.